{"cdcTestId":"2020-0017","testcaseName":"2nd dose of Moderna Covid-19 Vaccine at 28 days ","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1957-09-21T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-09-21T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-12-14T00:00:00","recommendedDate":"2022-12-14T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-09-21T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T09:33:38.012","generalDescription":"This test case describes when a patient is administered a second dose of the Moderna Covid-19 vaccine at 28 days after the first dose, that the dose is valid.  A booster dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. \nv4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 18 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).\nv4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series."}